University Hospital Bispebjerg and Frederiksberg
bispebjerghospital.dkTotal trials
66
Active
21
Phase 3
2
Total enrollment
267,120
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lithium Carbonate | — | — | — | — | — | 1 | |
| Lamotrigine | — | — | — | — | — | 1 | |
| bDMARDS | — | — | — | — | — | 1 | |
| Prescription Drugs | — | — | — | — | — | 1 |
Next readouts
- 2019-12-01
- 2027-12-01
- 2028-01
Top conditions
- Depression4
- Stroke3
- Sphenopalatine Ganglion Block3
- Atrial Fibrillation3
- Headache2
- Postdural Puncture Headache2
- Fecal Incontinence2
- Malignant Melanoma2
Frequently asked questions about University Hospital Bispebjerg and Frederiksberg
- How many clinical trials does University Hospital Bispebjerg and Frederiksberg have on ClinicalTrials.gov?
- University Hospital Bispebjerg and Frederiksberg is listed as the lead sponsor on 66 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital Bispebjerg and Frederiksberg's trials are in Phase 3?
- 2 of University Hospital Bispebjerg and Frederiksberg's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University Hospital Bispebjerg and Frederiksberg focus on?
- University Hospital Bispebjerg and Frederiksberg's most-studied conditions on ClinicalTrials.gov are Depression, Stroke, Sphenopalatine Ganglion Block, Atrial Fibrillation, Headache.
- When are University Hospital Bispebjerg and Frederiksberg's next clinical trial readouts?
- University Hospital Bispebjerg and Frederiksberg has 3 upcoming primary-completion readouts tracked here; the soonest is “Assessing Pain by the painDETECT Questionnaire (PDQ)”, expected around 2019-12-01.